Building on a successful pre-seed round, secured IP, and recent seminal publications in the antigen specific immune tolerance (ASIT) space, Nodal Therapeutics is seeking financing through seed investment as well as co-development partnering/licensing. The focus is on achieving rapid human PoC in autoimmune disease by advancing our best-in-class ASIT platform and leveraging our pre-clinical data in rodents and non-human primates.